Rimiducid

Generic Name: Rimiducid

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₇₈H_₉₈N_₄O_₂₀

CAS Number: 195514-63-7

Unique Ingredient Identifier: H564L1W5J2

Background: Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins and dimerizes them, triggering downstream signaling cascade. The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation.

Indication: Investigated for use/treatment in bone marrow transplant and graft versus host disease.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancers

The study evaluated BPX-601 with rimiducid in metastatic pancreatic and prostate cancers, focusing on safety, clinical activity, and translational activity. It was a multi-center, phase 1 dose-escalation trial, discontinued early due to DLT events impacting financing.

Related Clinical Trials:

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy